THE EFFECT OF COMBINATION THERAPY ON BONE METABOLISM
Keywords:
osteoporosis, densitometry, BMDAbstract
Combination therapy in both groups was significantly effective in influencing bone mineral density (BMD) L1-L4. Therapy using Forcal plus showed a significantly greater increase in BMD in the vertebrae. There was a significantly greater decrease in pain syndrome. In conclusion, it should be noted that Forcal plus is an effective treatment for osteoporosis (OP). Its long-term use in the complex therapy of various forms of OP leads not only to a progressive increase in BMD in the lumbar spine and proximal femur, but also to a decrease in the risk of vertebral fractures.
References
1. Akhpolova V.O., Brin V.B. Calcium metabolism and its hormonal regulation. Journal of Fundamental Medicine and Biology. № 2. 2017. (In Russian)
2. Kasimova M. B., Pulatova Sh. B. The compatibility of rheumatoid arthritis with other diseases //days of rheumatology in St. Petersburg-2018. – 2018. – pp. 94-96. (In Russian)
3. Lesnyak O. Clinical recommendations: diagnosis, prevention and treatment of glucocorticoid osteoporosis in men and women 18 years and older / O. Lesnyak, I. Baranova, N. Toroptsova. Yaroslavl: Litera, 2013. (In Russian)
4. Lesnyak O.M. Clinical recommendations for the prevention and management of patients with osteoporosis // Yaroslavl: Litera. — 2012. (In Russian)
5. Mkrtumyan A.M., Biryukova E.V. Bisphosphonates in the treatment of osteoporosis. Problems of Endocrinology. 2008;54(3):51-54. (In Russian)
6. O.L.Barabash et al.Atherosclerosis 2015, volume 11, No.2,pp.5-12. (In Russian)
7. Pulatova Sh.B., Nabieva D.A. Assessment of the impact of mineral metabolism disorders on quality of life in patients with ankylosing spondyloarthritis // "Neurology" – 2022. – №3 (91). - S.16-18. (In Russian)
8. Riggs B. L., And kl top III L. D. Osteoporosis. Etiology, diagnosis, treatment. - M., 2000. (In Russian)
9. Sagatova D.R., Nabieva D.A., Pulatova S.B. Evaluation of the effectiveness of bioregulatory drugs in the treatment of osteoarthritis in menopause with endothelial dysfunction. // Therapeutic Bulletin of Uzbekistan. 2023. №3. (In Russian)
10. Solovyova, E. Irreversible organ damage in patients with systemic lupus erythematosus. SLICC damage index / E. Solovyova [et al.] // Modern rheumatology. — 2016. (In Russian)
11. Skripnikova I.A., Oganov R.G. Osteoporosis and osteopathies. 2009. №2. (In Russian)
12. Tsarenok S.Yu. The relationship of bone mineral density and indicators of immune inflammation in women with osteoporosis in combination with coronary heart disease / S.Yu. Tsarenok, V.V. Gorbunov, T.A. Aksenova //Modern rheumatology. – 2014. – № 3. (In Russian)
13. Schwartz G. Ya. Pharmacotherapy of osteoporosis. - M., 2002. (In Russian)
14. Shukurova S.M., Mirzovaliev O.H. Osteoporosis in association with rheumatic diseases. Bulletin of the Academy of Medical Sciences of Tajikistan – Volume X, No. 1, 2020. (In Russian)
15. Briot, K. Glucocorticoid-induced osteoporosis / K. Briot, C. Roux // RMD Open. — 2015. — Vol. 1. — № 1. — e000014.
16. Buckley, L. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis / L. Buckley [et al.] // Arthritis and Rheumatology. — 2017. — Vol. 69. — № 8.
17. Cooper, C. Epidemiology of osteoporosis / C. Cooper, L. Melton // Trends in endocrinology and metabolism. — 1992. — Vol. 3. — № 6.
18. Kanis, J. European guidance for the diagnosis and management of osteoporosis in postmenopausal women / J. Kanis [et al.] // Osteoporosis international. — 2019.
19. Kanis, J. The diagnosis of osteoporosis / J. Kanis [et al.] // The Journal of bone. — 1994. — Vol. 9. — № 8.
20. Lau, E. Mortality following the diagnosis of a vertebral compression fracture in the Medicare population / E. Lau [et al.] // The journal of bone and joint surgery. — 2008. — Vol. 90. — № 7.
21. Lekamwasam, S. Framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis / S. Lekamwasam [et al.] // Osteoporosis international. — 2012. — Vol. 23.
22. Puisto, V. Vertebral fracture and cause-specific mortality: a prospective population study of 3,210 men and 3,730 women with 30 years of follow-up / V. Puisto [et al.] // European Spine Journal. — 2011. — Vol. 20. — № 12.
23. Pulatova Sh., Nabiyeva D., Abduazizova N., Mukhammadiyeva S., Agzamova G., Isayeva B. Clinical and pathogenetic values of disorders of mineral metabolism in ankylosing spondylitis // Philosophical Readings XIII.4. – 2022. – PP. 20-28.
24. Recommendations for the prevention and treatment of glucocorticoid–induced osteoporosis American College of Rheumatology Taskforce on Osteoporosis Guidelines. / American College of Rheumatology // Arthritis and rheumatology. — 1996. — Vol. 39. — № 11.
25. Shakhnoza P., Abdumalikovna N. D. Assessment of clinical-pathogenetic significance of impaired mineral metabolism in patients with ankylosing spondyloarthritis // Journal of biomedicine and practice. – 2022. – Т. 7. – №.5.
26. Van Staa, T. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy / T. Van Staa [et al.] // Arthritis and Rheumatology. — 2003. — Vol. 48. — № 11. Vol. 30.
27. WHO scientific group on the assessment of osteoporosis at the primary health care level / World Health Organization // Summary meeting report. — 2004.
28. J.A.Kanis European guidance for the diagnosis management of osteoporosis in postmenopausal women. Osteoporos Int (2013)24:23-57. F.Cosman et al Clinician’s Gulde to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 25:2359-2381.
